Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Cetuximab in BRAF V600E Mutant Metastatic Colorectal Cancer
NCT05004350Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib in colorectal cancer (CRC) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoints: Dose Limiting Toxicities at 28 days and Progression-Free Survival up to 116 weeks. Started Sep 2021; status: completed.
02
Drugs
encorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05004350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004350.